KRYS
Price
$137.17
Change
+$0.37 (+0.27%)
Updated
May 8 closing price
Capitalization
3.95B
94 days until earnings call
ORMP
Price
$2.29
Change
+$0.07 (+3.15%)
Updated
May 8 closing price
Capitalization
93.55M
19 days until earnings call
Ad is loading...

KRYS vs ORMP

Header iconKRYS vs ORMP Comparison
Open Charts KRYS vs ORMPBanner chart's image
Krystal Biotech
Price$137.17
Change+$0.37 (+0.27%)
Volume$534.87K
Capitalization3.95B
Oramed Pharmaceuticals
Price$2.29
Change+$0.07 (+3.15%)
Volume$44.41K
Capitalization93.55M
KRYS vs ORMP Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. ORMP commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and ORMP is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (KRYS: $137.17 vs. ORMP: $2.29)
Brand notoriety: KRYS and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 163% vs. ORMP: 49%
Market capitalization -- KRYS: $3.95B vs. ORMP: $93.55M
KRYS [@Biotechnology] is valued at $3.95B. ORMP’s [@Biotechnology] market capitalization is $93.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than KRYS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while ORMP’s TA Score has 6 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 6 bearish.
  • ORMP’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -17.21% price change this week, while ORMP (@Biotechnology) price change was +0.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.95B) has a higher market cap than ORMP($93.5M). KRYS has higher P/E ratio than ORMP: KRYS (33.45) vs ORMP (20.91). ORMP YTD gains are higher at: -5.372 vs. KRYS (-12.441). KRYS has higher annual earnings (EBITDA): 110M vs. ORMP (9.44M). KRYS has more cash in the bank: 598M vs. ORMP (142M). ORMP has less debt than KRYS: ORMP (429K) vs KRYS (7.26M). KRYS has higher revenues than ORMP: KRYS (291M) vs ORMP (0).
KRYSORMPKRYS / ORMP
Capitalization3.95B93.5M4,228%
EBITDA110M9.44M1,166%
Gain YTD-12.441-5.372232%
P/E Ratio33.4520.91160%
Revenue291M0-
Total Cash598M142M421%
Total Debt7.26M429K1,693%
FUNDAMENTALS RATINGS
KRYS vs ORMP: Fundamental Ratings
KRYS
ORMP
OUTLOOK RATING
1..100
5763
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
33100
SMR RATING
1..100
6779
PRICE GROWTH RATING
1..100
8553
P/E GROWTH RATING
1..100
9644
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (68) in the Pharmaceuticals Other industry is in the same range as KRYS (73) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (33) in the Pharmaceuticals Major industry is significantly better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that KRYS’s stock grew significantly faster than ORMP’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is in the same range as ORMP (79) in the Pharmaceuticals Other industry. This means that KRYS’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's Price Growth Rating (53) in the Pharmaceuticals Other industry is in the same range as KRYS (85) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to KRYS’s over the last 12 months.

ORMP's P/E Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for KRYS (96) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew somewhat faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSORMP
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IDRV29.930.60
+2.05%
iShares Self-Driving EV and Tech ETF
TMFG29.160.17
+0.59%
Motley Fool Global Opportunities ETF
JANZ33.370.09
+0.28%
TrueShares Structured Outcome JanuaryETF
QUS155.290.21
+0.14%
SPDR® MSCI USA StrategicFactors ETF
SMN15.68-0.42
-2.59%
ProShares UltraShort Materials

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.27%
ACLX - KRYS
60%
Loosely correlated
+6.27%
IDYA - KRYS
55%
Loosely correlated
+1.96%
CGON - KRYS
53%
Loosely correlated
+8.01%
XNCR - KRYS
51%
Loosely correlated
+10.08%
SNDX - KRYS
50%
Loosely correlated
+10.21%
More